bcl-xl

Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

ABT-737 is a BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w (EC50=30.3 nM/78.7 nM/197.8 nM). ABT-737 exhibits antitumor activity and anti-aging activity.

Navitoclax (ABT-263) is a potent oral Bcl-2 inhibitor that binds to Bcl-xL, Bcl-2, and Bcl-w proteins (Ki<1 nM), demonstrating antitumor activity and inducing apoptosis.

Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor.

CAY10404 (3-(4-METHYLSULPHONYLPHENYL)-4-PHENYL-5-T) is a potent and highly selective inhibitor of COX-2 and COX-1. It is also a potent inhibitor of PKB/Akt and MAPK signalling pathways and induces apoptosis in NSC-LC cells, with analgesic, anti-inflammatory and anti-cancer activities.

Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.

BM 957 is an effective Bcl-2 and Bcl-xL inhibitor (Kis: 1.2 and <1 nM; IC50s: 5.4 and 6.0 nM).

PDK4-IN-1 hydrochloride, an anthraquinone derivative, is a potent and orally active inhibitor of pyruvate dehydrogenase kinase 4 (PDK4) with an IC50 value of 84 nM.

S55746 hydrochloride is a potent, orally active and selective inhibitor of BCL-2(Ki of 1.3 nM and a Kd of 3.9 nM),with antitumor activity with low toxicity.

S55746 (BLC201) is an effective and selective BCL-2 inhibitor (Ki: 1.3 nM and a Kd of 3.9 nM).

WEHI-539 hydrochloride is a selective Bcl-XL inhibitor with an IC50 of 1.1 nM.

WEHI-539 is a selective Bcl-XL inhibitor (IC50: 1.1 nM).

(+)-Apogossypol is an antagonist of pan-BCL-2. (+)-Apogossypol binds to Mcl-1(Bcl-2 and Bcl-xL with EC50s of 2.6, 2.8 and 3.69 µM, respectively).

A-385358 is a selective Bcl-xL inhibitor with Kis of 0.80 nM for Bcl-xL and 67 nM for Bcl-2, respectively.

AZD4320 is an inhibitor of BH3-mimicking dual BCL2/BCLxL. For KPUM-MS3, KPUM-UH1, and STR-428 cells, the IC50s values are 26 nM, 17 nM, and 170 nM , respectively.

(S,R,S)-AHPC-Me-C7 ester is an E3 ligase ligand-linker conjugate used to synthesize BCL-XL PROTAC degraders[1].

Se-Aspirin (Se-NSAID-8) has anticancer activity and gastroprotective effects, inhibits activation of proinflammatory and pro-survival NF-ĸB pathways, and inhibits the expression of anti-apoptotic targets downstream of NF-ĸB (e.g., Bcl-xL, Mcl-1, and survivin).Se-Aspirin induces Cell cycle arrest and activation of apoptosis accelerates ulcer healing and can be used to study pancreatic and colorectal cancer.

MOMIPP is a PIKfyve inhibitor and a macropinocytosis inducer. MOMIPP readily penetrates the blood-brain barrier and is moderately effective in suppressing progression of intracerebral glioblastoma xenografts[1][2].

TW-37 is an nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 (Ki: 0.29/1.11/0.26 μM).

(R)-(-)-Gossypol acetic acid (AT101 acetate), the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL, and Mcl-1 with Ki values of 0.32 μM, 0.48 μM, and 0.18 μM, respectively; it does not inhibit the BIR3 domain or BID. [Phase 2]

A-1155463, a highly potent and selective BCL-XL inhibitor, shows picomolar binding affinity to BCL-XL, and >1000-fold weaker binding to BCL-2 and related proteins BCL-W(Ki=19 nM) and MCL-1(Ki>440 nM).

A-1331852 is a potent and selectiveBCL-XL inhibitor and may be useful in the treatment of cancer, immune and autoimmune diseases.

Dihydrokaempferol (Aromadendrin) is a natural product. It induces apoptosis and inhibits Bcl-2 and Bcl-xL expression, possesses anti-inflammatory, antioxidant, and anti-diabetic properties, it exhibits anti-inflammatory activity

BCL-XL-IN-1 (Compound 11) is a selective inhibitor of BCL-XL, exhibiting a Ki of less than 0.01 nM against BCL-XLTR-FERT. It is primarily used in cancer research.